-
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
03 Feb 2026 22:51 GMT
… we performed a drug screen by combining olaparib, an FDA-approved PARPi, … in oncology. Major pharmaceutical companies have developed more … Given that recent clinical trials indicate that the activity … and other DNA damaging drugs) treatments. A low-dose PRMTi …
-
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
03 Feb 2026 15:44 GMT
… -Breast02 Phase III trial which showed DATROWAY … TROP2-directed DXd antibody drug conjugate (ADC) … medicine camizestrant.
PARP inhibitor olaparib is a targeted treatment … : RESEARCH FDA CLINICAL TRIALS BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE …
-
From Teriparatide to Pembrolizumab: CDSCO Clears Import of r-DNA Drugs via CT-18 Route
26 Jan 2026 13:24 GMT
… the New Drugs and Clinical Trials Rules and … , Intas Pharmaceuticals Ltd’s Serplulimab, Sun Pharmaceutical Industries Ltd … combination with a statin or statin with other lipid lowering … maintenance treatment with Durvalumab in combination with olaparib in …
-
<![CDATA[A Year of Advancements in the Treatment of Cancer]]>
29 Dec 2025 20:15 GMT
…
AstraZeneca’s Lynparza (olaparib) was accepted for … two German biotechnology companies.
Regulatory cancer treatment approvals in … clinical trial for the small-molecule immunotherapy drug … Impact of FDA’s Guidance on Clinical Trials for Radiopharmaceuticals …
-
Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer
22 Dec 2025 11:00 GMT
… Biosplice”), a clinical-stage biotechnology company advancing small-molecule … -initiated trial, “Cirtuvivint and Olaparib for the Treatment of … University School of Medicine
About Cirtuvivint
Cirtuvivint … inhibitors. Biosplice’s drugs in clinical development …
-
<![CDATA[Trabectedin Plus Olaparib Improves PFS in Some Patients With STS]]>
22 Dec 2025 19:15 GMT
… and olaparib (Lynparza; AstraZeneca, Merck) may be a meaningful treatment for … to guide therapy.
One treatment option for advanced STS … , a phase 2 randomized trial, the investigators tested the … failure of anthracycline-based treatment (TOMAS2): a randomized …
-
<![CDATA[FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer]]>
18 Dec 2025 02:53 GMT
… and Drug Administration has granted regular approval to treatment with … the trial, Rubraca was associated with what the FDA described … inhibitors, such as Lynparza (olaparib) and Rubraca, were initially … agent therapies for the treatment of patients with …
-
Real-World Study of Olaparib in Chinese Ovarian Cancer
18 Dec 2025 01:50 GMT
… Among these innovative treatments, olaparib has emerged as … prospective, non-interventional drug intensive monitoring study conducted … olaparib performs outside the controlled environment of clinical trials … emphasis on personalized medicine, the findings from …
-
<![CDATA[RAD51 Test Predicts Olaparib Response in HER2– Breast Cancer]]>
15 Dec 2025 15:13 GMT
… from the phase 2 RADIOLA trial (NCT05340413) demonstrates that a … 82.3%), respectively.
“This trial supports the value of a … a biopsy was performed after treatment. Patients with HR-positive … of treatment in both cohorts, clinical benefit with olaparib by …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
16 Dec 2025 03:09 GMT
… Food and Drug Administration (FDA)-approved …
In the trial, ENHERTU in … medicine camizestrant.
PARP inhibitor olaparib is a targeted treatment … BIOTECHNOLOGY HEALTH WOMEN PHARMACEUTICAL ONCOLOGY OTHER SCIENCE RESEARCH GENETICS CONSUMER SCIENCE CLINICAL TRIALS …
About
© 1995-2026